Moderna's Melanoma Vaccine Trial Ignites Chatter
Moderna and Merck announced a positive Phase 3 melanoma trial, but reported stock gains conflict and no price was captured.
What's happening
Moderna and Merck said their mRNA neoantigen therapy met its primary endpoint in a Phase 3 melanoma trial by cutting recurrence, and several outlets called it a historic result for cancer vaccines. Headlines reported shares doubling, rising over 115%, and, in a Russian-language post, rising 150% in a single day. No price feed was captured to confirm any of those moves.
The numbers
No price was captured for MRNA, so none of the reported moves can be checked here. Chatter was 13 recent mentions across 3 sources, with a velocity of 13.0.
Our read
Watch - the trial result looks real since Merck co-announced it, but the size of the reported price pop is unverified and inconsistent across sources. Confirm against MRNA's actual tape before repeating any single number.
Context
No earlier Sort Brick stories on Moderna appear in this set, and no price history was captured, so the comparison relies on later stories and chatter counts. Later Sort Brick stories on Moderna are dated October 6 and October 23 and carry real and fake verdicts. One October 23 story reports the stock dropping as much as 26% on a reported data leak, while a same-day story rates the leak chatter fake because the price shows only a 1.5% gain. The later verdicts run in both directions, the same mismatch between chatter and price that the August 19 coverage shows.
Sources we checked
- Moderna shares double on melanoma vaccine trial success β Hacker News
- Moderna, Merck cancer vaccine shows promise in late-stage phase three trial β Hacker News
- Moderna cancer vaccine succeeds in historic Phase 3 trial, stock soars over 115% β Hacker News
- ΠΠΊΡΠΈΠΈ Moderna Π·Π° Π΄Π΅Π½Ρ ΠΏΠΎΠ΄ΠΎΡΠΎΠΆΠ°Π»ΠΈ Π½Π° 150% Π½Π° ΡΠΎΠ½Π΅ Π·Π°ΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ ΠΎΠ± ΡΡΠΏΠ΅Ρ Π°Ρ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΡΠΠΊΡΠΈΠΈ Π°ΠΌΠ΅ΡΠΈΠΊΠ°Π½ΡΠΊΠΎΠΉ Π±ΠΈΠΎΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΠΌΠΏΠ°Π½ΠΈΠΈ Moderna ΠΏΠΎΠ΄ΠΎΡΠΎΠΆΠ° β @meduza@zhub.link
- Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma β Hacker News
- Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in trial β Hacker News
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial β Hacker News
- Stock Movers: Moderna, Estee Lauder, La-Z-Boyhttps://www.bloomberg.com/news/audio/2026-08-19/stock-movers-moderna-estee-lauder-la-z-boy-podcast?utm_source=flipb β @bloomberg@flipboard.com
See today's live board
This story is frozen as published on August 19, 2026. The live board shows what is moving right now, scored against real money.
Open this story live β See today's live boardMore Stocks stories
- SoFi's Earnings Beat Comes With a Real Pop August 19, 2026
- Cerebras Rockets on CS-4, OpenAI Deal Talk August 19, 2026
- BlackRock Talks Up AI Power, Doubts Its Own Bitcoin Bet August 19, 2026
- Meta's $1.4 Trillion Trial Headline, Flat Stock August 19, 2026
- Amazon's AWS Beat Just Repriced the Stock August 19, 2026
- Rivian Guidance Raise Hasn't Moved the Stock August 19, 2026
Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything β you decide.